WO1994018994A1 - Composition therapeutique a base d'herbes - Google Patents

Composition therapeutique a base d'herbes Download PDF

Info

Publication number
WO1994018994A1
WO1994018994A1 PCT/US1994/002184 US9402184W WO9418994A1 WO 1994018994 A1 WO1994018994 A1 WO 1994018994A1 US 9402184 W US9402184 W US 9402184W WO 9418994 A1 WO9418994 A1 WO 9418994A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
amount
present
weight
zyelanicum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/002184
Other languages
English (en)
Inventor
Johel M. Neiron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHARMAKON USA Inc
Original Assignee
PHARMAKON USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHARMAKON USA Inc filed Critical PHARMAKON USA Inc
Priority to AU62743/94A priority Critical patent/AU6274394A/en
Publication of WO1994018994A1 publication Critical patent/WO1994018994A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus

Definitions

  • the subject invention relates generally to a therapeutic herbal composition, and in particular to a herbal composition which includes Trigonella foenum-graecum seed, Syzygium aromaticum fruit, Allilum sati ⁇ mm bulb, Cinnamonmum zyelanicum bark, Saussurea costus root and Euphorbia lathyris bud.
  • This therapeutic herbal composition is formed from a synergistic combination of herbs which are useful in lowering cholesterol, and treating arthritis, blood pressure and Alzheimer's disease. It is also useful as a bitters tonic, and has been approved as a bitters tonic by the Australian Therapeutic Goods Administration.
  • Japanese Patent Publication No. 4,005,237 teaches the combination of Cinnamomum sieboldii and Allium sativum for superoxide scavenging in the treatment of inflammatory disorders.
  • German Patent Publication No. 3,724,341 teaches the use of Cinnamomum zeylanicum as an anti-inflammatory agent which exerts a synergistic anti-inflammatory effect in combination with Pumica granitum cortex, Cardamon zingiberaceie fruit and Piper longu fruit.
  • composition of herbs described herein functions to produce a synergistic interaction, and thus represents a potential tool in the treatment of high cholesterol, arthritis, high blood pressure and Alzheimer's disease, as well as a general bitters tonic.
  • the subject invention provides a therapeutic composition which comprises Trigonella foenum-graecum seed,
  • Syzygium aromaticum fruit sativum bulb, Cinnamonmum zyelanicum bark, Saussurea costus root, and Euphorbia lathyris bud in amounts effective to produce a physiological benefit.
  • the subject invention will now be described in terms of its preferred embodiments. These embodiments are set forth to aid in the understanding of the subject invention, but are not to be construed as limiting.
  • the subject composition is that described below: wt. % of wt. % wt. range
  • composition supplies the physiologically important chemicals listed below:
  • the biological active components include choline and inositol.
  • the above herbs are typically dried and ground to a fine powder. All weights are expressed in milligrams and all percentages are by weight of the essential elements in the composition.
  • the composition is typically an intimate mixture of powders.
  • extracted herbs may also be used.
  • the known biological active components include choline and thiamine. Under normal conditions a 580 mg dose would be administered several times daily. The dosage of course may vary depending on body weight and other conditions readily determinable by those skilled in the art who have read the subject application. Administration is typically oral, with administration being via a capsule.
  • various fillers such as ash, may be present.
  • 100 people on a weight loss and lower lipid diet and taking a placebo 100 people without the diet and taking the subject composition. 100 people without diet and taking a placebo.
  • the purpose of the study was to determine whether the subject composition taken in capsule form 680 mg each (580 mg of the composition) , twice daily for 18 weeks, lowers:
  • Triglyceride reduced by 15-30% LDL/VLDL reduced by 1-7% Ratio Reduced by 9-20% HDL increased by 22% Dosage 12 capsules per day for the first 6 weeks, for study: Thereafter reduced to 8 capsules per day
  • the main bioactive ingredients include choline, thiamine HC1, ascorbic acid, nicotinic acid, lecithin and phytosterols, which are reported by the British Pharmacopoeia to be effective against coronary atherosclerosis and lowering high cholesterol and triglyceride levels.
  • the hygroscopicity to moisture content varies during storage and distribution from 6.8% to 10% while maintaining normal function.
  • the biodecomposition in digestibility test within 0.2% pepsin solution complies with analysis of Association of Analytical Chemists for 28% digestive residue at temperature 42°-45°C during 16 hours supporting good quality herbal ingredients.
  • Clinical research shows that ratios of HDL (High Density Lipoproteins) to LDL (Low Density Lipoproteins) lies in their respective functions for reduced blood cholesterol levels.
  • mis polyvinyl chloride bottles at range temperature 20- o 30°C. This prevents powder texture, white color and a bioactivity from changing as a result of variations in night and day temperatures, as well as keeping smell and taste unimpaired during storage. Moreover, the cholesterol lowering action of the subject composition is stabilized by radiation sterilization or using ethylene oxide penetration at elevated temperature, i.e. about 70°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Une composition thérapeutique à base d'herbes comprenant la graine Trigonella foenum-graecum, le fruit Syzygium aromaticum, le bulbe Allilum Sativum, l'écorce Cinnamonmum zyelanicum, la racine Saussurea costus et le bourgeon Euphorbia lathyris s'est révélée efficace afin de réduire le cholestérol et les triglycérides. Cette composition à base d'herbes peut s'utiliser pour abaisser le taux de cholestérol ainsi que pour le traitement de l'arthrite, la pression artérielle et la maladie d'Alzheimer. Elle est également efficace comme tonic amer.
PCT/US1994/002184 1993-02-23 1994-02-23 Composition therapeutique a base d'herbes Ceased WO1994018994A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU62743/94A AU6274394A (en) 1993-02-23 1994-02-23 Therapeutic herbal composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2103093A 1993-02-23 1993-02-23
US08/021,030 1993-02-23

Publications (1)

Publication Number Publication Date
WO1994018994A1 true WO1994018994A1 (fr) 1994-09-01

Family

ID=21801923

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/002184 Ceased WO1994018994A1 (fr) 1993-02-23 1994-02-23 Composition therapeutique a base d'herbes

Country Status (2)

Country Link
AU (1) AU6274394A (fr)
WO (1) WO1994018994A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707631A (en) * 1996-04-30 1998-01-13 Advanced Plant Pharmaceuticals Incorporated Therapeutic herbal composition
WO1999032097A3 (fr) * 1997-12-18 1999-09-02 Forbes Medi Tech Inc Procede pour prevenir et retarder l'apparition de la maladie d'alzheimer, et composition utilisee a cet effet
GB2335599A (en) * 1998-03-26 1999-09-29 Phytopharm Plc Treatment of conditions characterised by a deficiency in the number and function of membrane bound receptors using saponins and sapogenins
WO2005072253A3 (fr) * 2004-01-21 2006-06-08 Advanced Plant Pharmaceuticals Composition therapeutique a base de plantes medicinales amelioree destinee a traiter des maladies cardiovasculaires
US7138427B2 (en) 1999-03-26 2006-11-21 Phytopharm Plc. 5-β-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
WO2010041252A3 (fr) * 2008-10-07 2010-07-22 Ramot At Tel-Aviv University Ltd. Utilisation d'un extrait d'écorce de cannelle dans le traitement de maladies associées à l'amyloïde

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569839A (en) * 1981-02-27 1986-02-11 L'oreal Cosmetic compositions for the treatment of the hair and skin contain in the form of a powder particles resulting from the pulverization of at least one plant substance and a cohesion agent
US5073545A (en) * 1987-06-09 1991-12-17 Lion Corporation Agent containing an ellagic acid series compound for external application and use thereof
US5176913A (en) * 1988-06-24 1993-01-05 Emil Flachsmann Ag Process for preparing a partial extract containing the volatile in steam components and further lipophilic components of medical plants and/or spice plants

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569839A (en) * 1981-02-27 1986-02-11 L'oreal Cosmetic compositions for the treatment of the hair and skin contain in the form of a powder particles resulting from the pulverization of at least one plant substance and a cohesion agent
US4767618A (en) * 1981-02-27 1988-08-30 L'oreal Cosmetic compositions for the treatment of the hair and skin contain in the form of a powder particles resulting from the pulverization of at least one plant substance and a cohesion agent
US4933177A (en) * 1981-02-27 1990-06-12 Societe Anonyme Dite: L'oreal Cosmetic compositions for the treatment of the hair and skin contain in the form of a powder particles resulting from the pulverization of at least one plant substance and a cohesion agent
US5073545A (en) * 1987-06-09 1991-12-17 Lion Corporation Agent containing an ellagic acid series compound for external application and use thereof
US5176913A (en) * 1988-06-24 1993-01-05 Emil Flachsmann Ag Process for preparing a partial extract containing the volatile in steam components and further lipophilic components of medical plants and/or spice plants

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707631A (en) * 1996-04-30 1998-01-13 Advanced Plant Pharmaceuticals Incorporated Therapeutic herbal composition
WO1999032097A3 (fr) * 1997-12-18 1999-09-02 Forbes Medi Tech Inc Procede pour prevenir et retarder l'apparition de la maladie d'alzheimer, et composition utilisee a cet effet
GB2335599A (en) * 1998-03-26 1999-09-29 Phytopharm Plc Treatment of conditions characterised by a deficiency in the number and function of membrane bound receptors using saponins and sapogenins
GB2335599B (en) * 1998-03-26 2001-08-01 Phytopharm Plc Membrane-bound receptors and their function; cognitive disfunction; treatments therefor; and compositions for use in such treatments
US7507720B2 (en) 1998-03-26 2009-03-24 Phytopharm Plc 5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
US7138427B2 (en) 1999-03-26 2006-11-21 Phytopharm Plc. 5-β-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
WO2005072253A3 (fr) * 2004-01-21 2006-06-08 Advanced Plant Pharmaceuticals Composition therapeutique a base de plantes medicinales amelioree destinee a traiter des maladies cardiovasculaires
WO2010041252A3 (fr) * 2008-10-07 2010-07-22 Ramot At Tel-Aviv University Ltd. Utilisation d'un extrait d'écorce de cannelle dans le traitement de maladies associées à l'amyloïde

Also Published As

Publication number Publication date
AU6274394A (en) 1994-09-14

Similar Documents

Publication Publication Date Title
US6713096B2 (en) Dietary supplements and methods for treating pain and inflammation
JP4166951B2 (ja) 脳性および加齢性疾患の予防または治療のためのカルニチンおよびレスベラトロールの組み合わせ
US8563051B2 (en) Herbal composition for weight management
US20020136782A1 (en) Composition patent for solid-dosage form of weight loss product
US5707631A (en) Therapeutic herbal composition
DE602004006860T2 (de) Capsaicinoid enthaltende pharmazeutische zusammensetzung zur oralen verabreichung
US6656464B2 (en) Gastric emptying-promoting composition
US6773715B1 (en) Preparation and use of solidified oils
DE2921852A1 (de) Lipide senkendes mittel
WO1994018994A1 (fr) Composition therapeutique a base d'herbes
HU200687B (en) Process for producing pharmaceutical composition comprising bezafibrate as active ingredient and suitable for treating normolipidaemic diabetes
DE60104802T2 (de) Lebensmittel zur prävention von leberdysfunktion enthaltend ein alkanoyl l-carnitin und ein silybum marianum extrakt und verwendung desselben
EP0127297B1 (fr) Composition contenant des vitamines avec un taux d'absorption amélioré et méthode pour son administration
EP2445338A1 (fr) Combinaison synergique pour améliorer le métabolisme de l insuline et du glucose sanguin
JP2003024010A (ja) 緑茶カテキンを主成分とする機能強化補助食品
US20020197338A1 (en) Botanical composition and methods for the treatment or prevention of obesity
DE202008015430U1 (de) Zusammensetzung zur Behandlung von Verdauungsstörungen
JPS61238729A (ja) コレステロ−ル低下剤
DE202023001867U1 (de) Formulierung umfassend mindestens eine Kresse-Art
EP0724451B1 (fr) Procedes d'extraction et d'utilisation d'extrait vegetal du "muira puama"
US20160367617A1 (en) Herbal product for its administration to diabetic people and process to obtain it
JP7452777B2 (ja) 生活の質改善又は維持用組成物
JPH08208464A (ja) 高脂血症の治療及び予防薬
KR20010026440A (ko) 숙취 제거 및 간장 보호를 위한 조성물
US20050129788A1 (en) Herbal product to be administered to diabetic individuals and the production method thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD SK UA VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA